

FORM PTO-1.20 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		ATTORNEY'S DOCKET NUMBER GENE-120/02US
		U.S. APPLICATION NO. (If known, see 37 CFR 1.5) 10/580423
INTERNATIONAL APPLICATION NO. PCT/US2004/039593	INTERNATIONAL FILING DATE 24 November 2004	PRIORITY DATE CLAIMED 24 November 2003
TITLE OF INVENTION METHODS FOR MOLECULAR TOXICOLOGY MODELING		
APPLICANT(S) FOR DO/EO/US DIGGANS, James C., and ELASHOFF, Michael		
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:		
<p>1. <input type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.</p> <p>2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 37 U.S.C. 371.</p> <p>3. <input checked="" type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.</p> <p>4. <input type="checkbox"/> The US has been elected (Article 31).</p> <p>5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)) a. <input checked="" type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau). b. <input checked="" type="checkbox"/> has been communicated by the International Bureau. c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).</p> <p>6. <input type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)) a. <input type="checkbox"/> is attached hereto. b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4).</p> <p>7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau). b. <input type="checkbox"/> have been communicated by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input checked="" type="checkbox"/> have not been made and will not be made.</p> <p>8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).</p> <p>9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).</p> <p>10. <input type="checkbox"/> An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).</p>		
<p>Items 11 to 20 below concern document(s) or information included:</p> <p>11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.</p> <p>12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.</p> <p>13. <input type="checkbox"/> A preliminary amendment.</p> <p>14. <input type="checkbox"/> An Application Data Sheet under 37 CFR 1.75.</p> <p>15. <input type="checkbox"/> A substitute specification.</p> <p>16. <input type="checkbox"/> A change of power of attorney and/or address letter.</p> <p>17. <input checked="" type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 – 1.825.</p> <p>18. <input type="checkbox"/> A second copy of the published international application under 35 U.S.C. 154(d)(4).</p> <p>19. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).</p> <p>20. <input type="checkbox"/> Other items or information:</p>		

US Application No.

10/580423

Intr. Application No.

PCT/US2004/039593

Attorney Docket No.

GENE-120/02US

		The following fees are submitted:	CALCULATIONS	PTO USE ONLY	
21.	X	Basic national fee (37 CFR 1.492(a)) \$300.00	\$ 300.00		
22.	X	Examination fee (37 CFR 1.492(c)) If the written opinion prepared by ISA/US or the international preliminary examination report prepared by IPEA/US indicates all claims satisfy provisions of PCT Article 33(1)-(4) \$0.00 All other situations \$200.00	\$ 200.00		
23.	X	Search fee (37 CFR 1.492(b)) If the written opinion prepared by ISA/US or the International preliminary examination report prepared by IPEA/US indicates all claims satisfy provisions of PCT Article 33(1)-(4) \$0.00 Search fee (37 CFR 1.445(a)(2)) has been paid on the international application to the USPTO as an International Searching Authority \$100.00 International Search Report prepared by an ISA other than the US and provided to the Office or previously communicated to the US by the IB \$400.00 All other situations \$500.00	100.00		
TOTAL OF 21, 22 AND 23 =					
[]		Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing in compliance with 37 CFR 1.821(c) or (3) or computer program listing in an electronic medium) (37 CFR 1.492(j)). The fee is \$250.00 for each additional 50 sheets of paper or fraction thereof.			
Total Sheets	Extra Sheets	Number of each additional 50 or fraction thereof (round up to a whole number)	RATE		
74-100=	/50 =	0	x \$250.00		
Surcharge of \$130.00 for furnishing any of the search fee, examination fee, or the oath or declaration after the date of commencement of the national stage (37 CFR 1.492(h)).			\$ 130.00		
CLAIMS		NUMBER FILED	NUMBER EXTRA	RATE	
Total claims		55- 20 =	35	x \$50.00 \$1750.00	
Independent claims		4- 3 =	1	x \$200.00 \$ 200.00	
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$370.00	\$	
TOTAL OF ABOVE CALCULATIONS =				\$2680.00	
[] Applicant claims small entity status. See 37 CFR 1.27. Fees above are reduced by ½.				\$	
SUBTOTAL =				\$2680.00	
Processing fee of \$130.00 for furnishing the English translation later than [] 20 [] 30 months from the earliest claimed priority date (37 CFR 1.492(i)).				\$	
TOTAL NATIONAL FEE =				\$2680.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +				\$	
TOTAL FEES ENCLOSED =				\$2680.00	
				Amount to be refunded: \$	
				charged: \$	
a. [] A check in the amount of \$ to cover the above fees is enclosed.					
b. X Please charge my Deposit Account No. 50-1283 in the amount of \$2680.00 to cover the above fees. A duplicate copy of this sheet is enclosed.					
c. [] The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No (PA) 03-3117 (RE/DC) 50-1283. A duplicate copy of this sheet is enclosed.					
NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the International application to pending status.					

US Application No.

10/580423Intr. Application No.
PCT/US2004/039593Attorney Docket No.
GENE-120/02US

SEND ALL CORRESPONDENCE TO:

COOLEY GODWARD LLP
ATTN: Patent Group
The Bowen Building
875 15th Street, NW Suite 800
Washington, DC 20005-2221
Tel: (202) 842-7XXX or (703) 456-8000 or (720)
566-4XXX
Fax: (202) 842-7899 or (703) 456-8100 or (720)
566-4099

SIGNATUREHong Liu

NAME54,891

REGISTRATION NUMBERCUSTOMER NUMBER: **58249**

37977 v1/DC

PAT Rec'd PCT/PTO 24 MAY 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PLEASE DATE STAMP AND RETURN TO SHOW RECEIPT OF:

Int'l Appln. No.: PCT/US2004/039593
Applicant: DIGGANS, James C. et al
Filing Date: 24 May 2006

For: METHODS FOR MOLECULAR TOXICOLOGY
MODELING

1. Transmittal Form - 3 pages (in duplicate)
2. State Accompanying Sequence Listing with 2 CDs
containing the Sequence Listing
3. International Application Published Under the Patent
Cooperation Treaty (PCT) - 75 pages
4. (2) Return Receipt Postcards
ICMQ

Dated: May 22, 2006
Atty. Docket No.: GENE-120/02USUS

Client/Matter No.: 071912-
Atty/Secy: HL/gsk

10/580423

37985 v1DC